GCCA
20.2.2024 13:31:29 CET | Business Wire | Press release
A pioneering international programme, which brings together tech start-ups and leading manufacturers in the pursuit of net zero, has launched.
Innovandi Open Challenge 2024 is run by the Global Cement and Concrete Association (GCCA), the industry’s leading international body which is focused on helping the global cement industry reduce its emissions and ultimately achieve net zero concrete.
Applications are being encouraged from start-ups from around the world, interested in working on the development of carbon capture use and storage, for low carbon cement and concrete. Innovative technologies are sought, which include process integrated and end-of-pipe CO2 capture and use, and help prevent the carbon being emitted into the atmosphere.
This will be the 3rd Innovandi Open Challenge and builds on the success of previous years. The first challenge, in 2022, also focused on the development of carbon capture technology, and two start-ups have already gone to pilot stage. The 15 start-ups shortlisted in last year’s 2nd Innovandi Challenge, to work on the development of low carbon concrete, are currently in discussion with manufacturers about forming partnerships.
Claude Loréa, the GCCA’s Cement, Innovation and ESG Director, said: “Our industry is committed to achieving net zero and the development of carbon capture technology is a key part of that work. Our world leading Innovandi Open Challenge programme has already seen remarkable progress being made in just two years, with start-ups and our member companies working together. We’re looking forward to seeing what this year’s applicants can bring, to build on the extensive work that is already underway across the world.”
All GCCA members who account for 80% of global cement production capacity outside of China, and a number of leading Chinese manufacturers, have committed to reaching net zero, by 2050, through the GCCA’s Concrete Future 2050 Net Zero Roadmap – the first global industry to set out such a detailed plan. The GCCA has also recently signed a ground-breaking agreement to work together on decarbonisation with the China Cement Association (CCA).
The development of new technologies is a key part of the industry’s roadmap to net zero, and carbon capture and storage technology is expected to account for around 36% of total emission reductions by 2050.
The industry’s first industrial-scale cement plant equipped with CO2 capture technology is scheduled to be mechanically completed at the Heidelberg Materials site in Brevik, Norway, by the end of 2024, with several more plants expected to open by 2030.
Thomas Guillot, Chief Executive of the GCCA, said: “We already know CCUS technology works, with pilots and projects underway across the world, but it’s crucial to see what other innovations are out there, beyond our industry, that could help accelerate our net zero mission.
“We encourage applications from start-ups around the globe to join us in the urgent fight to limit global warming. If you are a start up from Austria to Australia, from Brazil to Bangladesh, with an innovative idea or technology to further develop CCUS, then you should be applying.”
Jonathan Cool, CEO of Ultra High Materials, a start-up which participated in last year’s Open Challenge, encouraged others to apply: “The support, guidance, exposure to the GCCA membership and the facilitation of collaborative opportunities with GCCA members has been effective, efficient and it's made a beneficial impact for all of us. Given the option to do it all again, we certainly would.”
Start-ups interested in applying to the third Innovandi Open Challenge, can click here for more information. The deadline for applications is 15th April.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220364304/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 03:00:00 CEST | Press release
Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202627.5.2026 23:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEAOral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1 <1% BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei Univ
Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 17:22:00 CEST | Press release
The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College
Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 16:00:00 CEST | Press release
As buyers face tighter budgets, Capchase helps technology companies close more deals faster with AI-enabled instant financing Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks wi
ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 15:00:00 CEST | Press release
Annual run-rate revenue more than tripled year-over-year; new CostBench benchmark shows ClickHouse Cloud at 23x better cost-performance than the nearest cloud data warehouse ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
